Acadian Asset Management LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 581.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,620,146 shares of the biopharmaceutical company’s stock after buying an additional 2,235,684 shares during the period. Acadian Asset Management LLC’s holdings in Pfizer were worth $92,253,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in PFE. Catamount Wealth Management increased its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. increased its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Financial Strategy Network LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $205,000. Oakmont Partners LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $211,000. Finally, Arete Wealth Advisors LLC increased its stake in shares of Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 726 shares during the period. Hedge funds and other institutional investors own 69.66% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer Inc. (NYSE:PFE) traded down 0.18% on Wednesday, reaching $33.07. The company’s stock had a trading volume of 15,138,664 shares. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The firm’s 50-day moving average price is $34.20 and its 200-day moving average price is $34.27. The stock has a market cap of $200.59 billion, a P/E ratio of 29.32 and a beta of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.56 EPS. On average, analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.63%. Pfizer’s payout ratio is 95.24%.

A number of analysts have recently issued reports on the stock. Argus reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a report on Tuesday, October 4th. Bank of America Corp. reiterated a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a report on Tuesday, September 27th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group lowered their price objective on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Finally, Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 23rd. Ten investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.